Komori
Astellas Pharma (4503) · Risk通期の主要卸売業者売上実績の更新

Sales Concentration in U.S. Wholesalers

First written in FY2023. 2 of 5 entries say "Restated". Latest entry: FY2026.

5entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023 – FY20262023: 220232024: 120242025: 120252026: 12026
Same theme, other companies
Disclosure of Major Customers and Customer Sales MixA theme 16 companies write about · 12 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2024: 2 of 12 companies on the "Worse" side.

10 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 16 companies compared. The sentences above are computed from all 16.
Full recordFilings, disclosures and news, newest first
  1. FY2026通期の主要卸売業者売上実績の更新Annual report

    「McKesson Group 291,485 15.2% Cencora Group 271,974 14.2%」

    米国卸売業者への売上集中について、当年度はMcKesson Groupが連結売上収益の14.6%、Cencora Groupが14.4%を占める実績を開示した。
  2. FY2025通期の主要卸売業者売上実績の更新Annual report

    「McKesson Group 291,485 15.2% Cencora Group 271,974 14.2%」

    米国卸売業者への売上集中について、McKesson Groupが連結売上収益の15.2%、Cencora Groupが14.2%を占める実績を開示した。
  3. FY2024-Q3RestatedAnnual report

    「During the nine-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    米国卸売業者への売上集中を含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  4. FY2024-Q1RestatedAnnual report

    「During the three-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    米国卸売業者への売上集中を含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  5. FY2023First statedAnnual report

    「McKesson Group 259,992 17.1% AmerisourceBergen Group 166,934 11.0%」

    米国の主要卸売業者であるMcKesson Group及びAmerisourceBergen Groupへの販売額が、それぞれ連結売上収益の17.1%及び11.0%を占めることを開示した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.